Trial Profile
A Randomized Phase II Study of Erlotinib Alone Versus Erlotinib Plus Bevacizumab for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AvaTa
- 30 Nov 2022 Primary endpoint (PFS) has not been met according to results published in the Cancer
- 30 Nov 2022 Results assessing addition of bevacizumab to erlotinib improves clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer published in the Cancer
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology